Literature DB >> 7474903

Phenylketonuric patients decades after diet.

R O Fisch1, P N Chang, S Weisberg, P Guldberg, F Güttler, M Y Tsai.   

Abstract

Nineteen early-treated phenylketonuric patients, whose diet was discontinued between 4.5 and 13 years of age, and who have been off the diet for 12-28 years, were reassessed in 1992-93. There was little change in mean IQ between end of diet and follow-up, less than one IQ point on the average, with no change for any individual exceeding 12 IQ points. Both prior and current IQ correlated slightly negatively with mean phenylalanine (Phe) concentration, and positively with parents' education. The phenylalanine level at follow-up was significantly lower on average by about 900 mumol/L. Five of the subjects (26%) have evidence of mental disease. However, the data suggest that the discontinuation of the diet did not cause intellectual deterioration. Nonetheless, the patients' intellect cannot be the only consideration for maintenance of diet. The occurrence of psychopathology among phenylketonuric patients and the possible unknown effects of toxic elevation of phenylalanine during their lifetime suggest the need to maintain the diet. The use of DNA for diagnostic and prognostic purposes might assist in decisions about dietary quality and duration, and in anticipation of psychopathology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474903     DOI: 10.1007/bf00710427

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  26 in total

1.  Intellectual and school performances in early-treated classical PKU patients. The French collaborative study.

Authors:  J M Saudubray; F Rey; H Ogier; V Abadie; J P Farriaux; J Ghisolfi; P Guibaud; J Rey; M Vidailhet
Journal:  Eur J Pediatr       Date:  1987       Impact factor: 3.183

2.  Spasticity and white matter abnormalities in adult phenylketonuria.

Authors:  P A McCombe; D B McLaughlin; J B Chalk; N N Brown; J J McGill; M P Pender
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

3.  Neurological disturbance in a phenylketonic child after discontinuation of dietary treatment.

Authors:  B Wood
Journal:  Dev Med Child Neurol       Date:  1976-10       Impact factor: 5.449

4.  Diet policies of PKU clinics in the United States.

Authors:  V E Schuett; E S Brown
Journal:  Am J Public Health       Date:  1984-05       Impact factor: 9.308

5.  Blood phenylalanine levels and intelligence of 10-year-old children with PKU in the National Collaborative Study.

Authors:  K Michals; C Azen; P Acosta; R Koch; R Matalon
Journal:  J Am Diet Assoc       Date:  1988-10

6.  Correlates of intelligence test results in treated phenylketonuric children.

Authors:  M L Williamson; R Koch; C Azen; C Chang
Journal:  Pediatrics       Date:  1981-08       Impact factor: 7.124

7.  Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria.

Authors:  N A Holtzman; R A Kronmal; W van Doorninck; C Azen; R Koch
Journal:  N Engl J Med       Date:  1986-03-06       Impact factor: 91.245

8.  Psychological and social findings in adolescents with phenylketonuria.

Authors:  J Weglage; B Fünders; B Wilken; D Schubert; E Schmidt; P Burgard; K Ullrich
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

9.  Mutational spectrum of phenylalanine hydroxylase deficiency in Sicily: implications for diagnosis of hyperphenylalaninemia in southern Europe.

Authors:  P Guldberg; V Romano; N Ceratto; P Bosco; M Ciuna; A Indelicato; F Mollica; C Meli; M Giovannini; E Riva
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

10.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

View more
  10 in total

1.  A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study.

Authors:  S H L Yi; J A Kable; M L Evatt; R H Singh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-10-14       Impact factor: 4.006

2.  Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity.

Authors:  Melissa Saichi; Maha Zohra Ladjemi; Sarantis Korniotis; Christophe Rousseau; Zakaria Ait Hamou; Lucile Massenet-Regad; Elise Amblard; Floriane Noel; Yannick Marie; Delphine Bouteiller; Jasna Medvedovic; Frédéric Pène; Vassili Soumelis
Journal:  Nat Cell Biol       Date:  2021-05-10       Impact factor: 28.824

3.  Large neutral amino acids in the treatment of phenylketonuria (PKU).

Authors:  R Matalon; K Michals-Matalon; G Bhatia; E Grechanina; P Novikov; J D McDonald; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2006-09-21       Impact factor: 4.982

4.  Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases.

Authors:  T Mlčoch; R Puda; P Ješina; M Lhotáková; Š Štěrbová; T Doležal
Journal:  Eur J Clin Nutr       Date:  2017-06-28       Impact factor: 4.016

5.  A cross-sectional study of docosahexaenoic acid status and cognitive outcomes in females of reproductive age with phenylketonuria.

Authors:  Sarah H L Yi; Julie A Kable; Marian L Evatt; Rani H Singh
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

Review 6.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

7.  Executive function impairment in early-treated PKU subjects with normal mental development.

Authors:  V Leuzzi; M Pansini; E Sechi; F Chiarotti; Cl Carducci; G Levi; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

8.  Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

Authors:  R Matalon; K Michals-Matalon; G Bhatia; A B Burlina; A P Burlina; C Braga; L Fiori; M Giovannini; E Grechanina; P Novikov; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2007-02-27       Impact factor: 4.750

Review 9.  Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria.

Authors:  Deborah A Bilder; J Kay Noel; Erin R Baker; William Irish; Yinpu Chen; Markus J Merilainen; Suyash Prasad; Barbara J Winslow
Journal:  Dev Neuropsychol       Date:  2016-11-02       Impact factor: 2.253

10.  Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids.

Authors:  D Concolino; I Mascaro; M T Moricca; G Bonapace; K Matalon; J Trapasso; G Radhakrishnan; C Ferrara; R Matalon; P Strisciuglio
Journal:  Eur J Clin Nutr       Date:  2016-09-14       Impact factor: 4.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.